Prognostic molecular markers in early breast cancer.
Prognostic molecular markers in early breast cancer.
复制标题
DOI:
10.1186/bcr777
复制
发表时间:
2004
期刊:
影响因子:
--
通讯作者:
Hortobagyi GN
中科院分区:
文献类型:
--
作者:
Esteva FJ;Hortobagyi GN
A multitude of molecules involved in breast cancer biology have been studied as potential prognostic markers. In the present review we discuss the role of established molecular markers, as well as potential applications of emerging new technologies. Those molecules used routinely to make treatment decisions in patients with early-stage breast cancer include markers of proliferation (e.g. Ki-67), hormone receptors, and the human epidermal growth factor receptor 2. Tumor markers shown to have prognostic value but not used routinely include cyclin D1 and cyclin E, urokinase-like plasminogen activator/plasminogen activator inhibitor, and cathepsin D. The level of evidence for other molecular markers is lower, in part because most studies were retrospective and not adequately powered, making their findings unsuitable for choosing treatments for individual patients. Gene microarrays have been successfuly used to classify breast cancers into subtypes with specific gene expression profiles and to evaluate prognosis. RT-PCR has also been used to evaluate expression of multiple genes in archival tissue. Proteomics technologies are in development.
登录
查看更多内容
影响因子:
8.8
作者:
Broët, P;Spyratos, F;Romain, S;Quillien, V;Daver, A;Ricolleau, G;Rallet, A;Toulas, C;Asselain, B
通讯作者:
Asselain, B
影响因子:
8.8
作者:
Bouchet, C;Spyratos, F;Martin, P M;Hacene, K;Gentile, A;Oglobine, J
通讯作者:
Oglobine, J
影响因子:
3.5
作者:
Bertucci, F;Nasser, V;Houlgatte, R
通讯作者:
Houlgatte, R
DOI:
10.1111/j.1749-6632.2002.tb05954.x
发表时间:
2002-01-01
期刊:
MICROARRAYS, IMMUNE RESPONSES AND VACCINES
影响因子:
--
作者:
Bertucci, F;Houlgatte, R;Nguyen, C
通讯作者:
Nguyen, C
影响因子:
2.2
作者:
Buchholz, TA;Davis, DW;Sahin, AA
通讯作者:
Sahin, AA